ADHD, Perimenopause and Menopause: What Is Known and What Is Not

Search for ADHD and perimenopause and you will find confident explanations involving estrogen and dopamine, lists of symptoms and advice about adjusting medication. Very little of it rests on studies of women in this stage of life. This page separates what has been measured from what is clinical opinion, and says plainly where the evidence runs out.

Why the question comes up so often now

More women are being diagnosed and treated for ADHD in midlife than before. A study in JAMA Psychiatry reported that the number of US women aged 35 to 64 dispensed stimulants rose from 1.2 million in early 2019 to 1.7 million in late 2022. CDC data on commercially insured adults show the share of women aged 50 to 54 filling a stimulant prescription rising from 2.5% to 2.9% between 2020 and 2021.

Many of these women were not identified as children. The National Institute of Mental Health notes that symptoms in girls and women are especially likely to have been missed. A woman diagnosed at 45 will reach perimenopause within a few years of starting treatment, or will be diagnosed in the middle of it. The site's article on late diagnosis in women covers that history.

What the research shows so far

Three recent publications represent the state of knowledge. Their conclusions do not agree.

The Icelandic authors read their results as suggesting that perimenopausal symptoms appear at an earlier age in women with ADHD. The UK authors concluded that women with ADHD do not experience greater menopausal complaints. They did find that ADHD symptom scores and menopausal complaints rose together across all participants, and suggested that women with ADHD may attribute symptoms differently.

The 2026 review states that current practice relies on expert consensus, extrapolation from younger groups and small observational studies. A third survey, published in 2026 and drawn largely from ADHD support groups and social media, reported greater menopausal symptom severity among women with self-reported ADHD.

What is not known

• Whether perimenopause worsens ADHD itself. No study has followed women with ADHD through the transition, measuring symptoms before, during and after.
• Whether hormones are the cause. The idea that falling estrogen affects attention through dopamine is a hypothesis. The surveys above did not measure hormones.
• Whether ADHD medication works differently in perimenopause. No randomized trial has tested it.
• Whether menopausal hormone therapy helps ADHD symptoms. The 2026 review lists trials of hormone therapy combined with stimulants as a research priority, which means they have not been done.
• How to adjust treatment. No evidence-based protocol exists.

Symptoms that overlap

One point has good support: the two are hard to tell apart from symptoms alone. The 2026 review describes diagnostic complexity arising from overlap between ADHD and perimenopausal symptoms, and lists sleep disruption and cognitive complaints such as brain fog and memory lapses among the features of the transition. Poor sleep alone can impair attention, and research in adults with ADHD shows they already take longer to fall asleep and sleep less efficiently.

That leaves three possibilities for a woman in her forties or fifties with worsening focus:

1. Long-standing ADHD that is now harder to compensate for.
2. Effects of the menopausal transition, including poor sleep and mood changes, in someone who does not have ADHD.
3. Both together.

The diagnostic criteria decide between the first two. ADHD requires several symptoms before age 12. Concentration problems that first appear in midlife, with no earlier pattern, do not meet that standard and are assessed for other causes. See can you develop ADHD as an adult? Depression can also surface at this stage and has its own page: ADHD and depression in adults.

What clinicians can do without strong evidence

An absence of trials does not leave women without care. It means decisions are individual and should be described honestly as such.

• Establish the history. An evaluation looks for the childhood pattern and for current impairment, as at any age.
• Check other causes. The CDC lists sleep disorders, anxiety and depression among conditions with similar symptoms, and CHADD notes that evaluation includes a medical exam to rule out causes such as thyroid problems.
• Review treatment already in place. A woman already on ADHD medication who notices a change can raise it with her prescriber. Changes are made by the prescriber, not by the patient alone.
• Watch blood pressure. Stimulant labels direct prescribers to monitor blood pressure and pulse, and the 2026 review includes cardiovascular monitoring in its practical guidance.
• Coordinate. The same review emphasizes interdisciplinary care. Hormone therapy is a decision for a gynecologist or primary care clinician, and the ADHD prescriber should know about it.

How to raise it at an appointment

• Note when the change in focus, memory or mood began and whether your cycle changed around the same time.
• Keep a brief record for a few weeks: sleep, hot flashes or night sweats, cycle dates and how well your usual strategies or medication worked each day.
• Bring a full list of medications and supplements, including any hormone therapy.
• Bring recent blood pressure readings if you have them.
• Tell each clinician what the other has prescribed.
• Ask directly what is known and what is a reasonable trial. A good answer will admit the uncertainty.

The practice's treatment page explains how medication is managed and reviewed, and the ADHD in Women and Across Adulthood hub collects related articles.

If you have not been evaluated and are deciding where to start, the comparison to read next is who can diagnose and treat adult ADHD in New York.